Epidermal growth factor receptor inhibitors in neuro-oncology: hopes and disappointments.

Details

Serval ID
serval:BIB_EC80AD269655
Type
Article: article from journal or magazin.
Publication sub-type
Review (review): journal as complete as possible of one specific subject, written based on exhaustive analyses from published work.
Collection
Publications
Title
Epidermal growth factor receptor inhibitors in neuro-oncology: hopes and disappointments.
Journal
Clinical Cancer Research
Author(s)
Brandes A.A., Franceschi E., Tosoni A., Hegi M.E., Stupp R.
ISSN
1078-0432
Publication state
Published
Issued date
2008
Peer-reviewed
Oui
Volume
14
Number
4
Pages
957-960
Language
english
Abstract
Despite advances in diagnosis and treatment made over the past two decades, high-grade gliomas are still incurable neoplasms. Moreover, after failing adjuvant therapy, few active treatments are available. In this setting, novel agents, such as new chemotherapy compounds and anticancer agents against specific molecular targets, have therefore been investigated. Epidermal growth factor receptor (EGFR) is an intriguing target in high-grade gliomas because it is frequently overexpressed due to amplification of the EGFR gene. Gefitinib and erlotinib act as ATP mimetic agents, binding to the cytoplasmic ATP pocket domain and blocking receptor phosphorylations and, thereby, EGFR-mediated activation of downstream pathways. These drugs have been evaluated in several clinical trials treating recurrent high-grade gliomas with contrasting results. Retrospective correlative analyses generated a plethora of putative predictive factors of activity of EGFR tyrosine kinase inhibitors. The first generations of studies on EGFR inhibitors have not found significant activity of these agents in high-grade gliomas. Furthermore, no clear molecular or clinical predictors have been identified. As with other targeted agents, prospective trials using specific criteria and standardized methods to evaluate tissue biomarkers are required to find predictors of EGFR inhibitors activity in high-grade glioma patients.
Keywords
Animals, Antineoplastic Agents, Brain Neoplasms, Glioma, Humans, Receptor, Epidermal Growth Factor
Pubmed
Web of science
Open Access
Yes
Create date
25/02/2008 23:59
Last modification date
09/05/2019 3:02
Usage data